Treats HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic…. Sold as Ziihera. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Zanidatamab-Hrii (sold as Ziihera), first approved Nov 20, 2024, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| ZIIHERA | Part B | $4.5M | New | 42 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent TreatmentColon Carcinoma, Colorectal Carcinoma · Emory University | Phase 2 | Recruiting | Feb 12, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Nov 20, 2024 | ZiiheraBLA 761416 · New molecular entity | Jazz Pharms | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA